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Summary
The p53 family comprises the tumor suppressor p53 and the structural homologs p63 and p73. How the three familymembers
cooperate in tumor suppression remains unclear. Here, we report different but complementary functions of the individual
members for regulating retinoblastoma protein (RB) function during myogenic differentiation. Whereas p53 transactivates
the retinoblastoma gene, p63 and p73 induce the cyclin-dependent kinase inhibitor p57 to maintain RB in an active, hypo-
phosphorylated state. DNp73 inhibits these functions of the p53 family in differentiation control, prevents myogenic differ-
entiation, and enables cooperating oncogenes to transformmyoblasts to tumorigenicity.DNp73 is frequently overexpressed
in rhabdomyosarcoma and essential for tumor progression in vivo. These findings establish differentiation control as a key
tumor suppressor activity of the p53 family.Introduction
The tumor suppressor gene p53 is central to an intricate network
of pathways that senses various types of cellular stress to coor-
dinate cell fate decisions such as cell cycle arrest, senescence,
or apoptosis (Vogelstein et al., 2000). p53 is a key regulator pre-
venting genotoxic stress and thus cancer progression. How-
ever, the physiological role of p53 in normal (unstressed) cells
is still a matter of debate.
It has been suggested for a long time that p53 might have im-
portant functions in the control of differentiation and develop-
ment. p53 is highly expressed in the mouse embryo (Choi and
Donehower, 1999), and p53 expression or activity is increased
during differentiative processes such as hematopoiesis, sper-
matogenesis, andmyogenesis (Almog and Rotter, 1997). In sup-
port of a critical role for p53 in cellular differentiation, alterations
of p53 in tumors frequently correlate with undifferentiated can-
cer phenotypes, and reconstitution of wild-type p53 triggers dif-
ferentiation in a variety of tumor cells (Almog and Rotter, 1997).CANCER CELL 10, 281–293, OCTOBER 2006 ª2006 ELSEVIER INC. DOConversely, the developmental viability of p53 null mice proves
the contrary (Choi and Donehower, 1999). Apart from neural
tube closure defects and reduced fertility, the lack of further de-
velopmental abnormalities suggests that p53 function is dis-
pensable for mammalian development (Choi and Donehower,
1999).
Besides p53, p63 and p73 are members of the p53 family that
share >60% amino acid identity within the DNA-binding domain
and regulate an overlapping set of target genes (Kaghad et al.,
1997; Yang et al., 1998). In addition, p63 and p73 display essen-
tial, nonredundant functions during development. p63-deficient
mice exhibit striking epithelial defects, including complete ab-
sence of skin, hair, and further ectodermal derivatives (Mills
et al., 1999; Yang et al., 1999). In contrast, p73-deficient mice
suffer from hippocampal dysgenesis, hydrocephalus, chronic
infections, and inflammation, as well as abnormalities in phero-
mone sensory pathways (Yang et al., 2000). Simultaneous inhi-
bition of all p53 family members by deregulated expression of
the antagonistic p73 isoformDNp73 induces embryonic lethalityS I G N I F I C A N C E
The role of p53 as a tumor suppressor is generally attributed to its ability to induce cell cycle arrest or apoptosis in response to genotoxic
and oncogenic stress. However, potential tumor suppressor activities of the structural p53 homologs p63 and p73 are still a matter of
debate. Here, we demonstrate that in myoblasts all three p53 family members cooperate in differentiation control. Ablation of these
p53 family functions blocks the differentiation program and promotes malignant transformation. Induction of cellular differentiation
therefore contributes to the tumor suppressor activities of the p53 family and provides an explanation for the high frequency of p53
pathway alterations in rhabdomyosarcoma patients.I 10.1016/j.ccr.2006.08.024 281
A R T I C L E(Erster et al., 2006; Hu¨ttinger-Kirchhof et al., 2006). This pheno-
type is more severe than the homozygous knockout of any sin-
gle p53 family member, suggesting that there are overlapping
functions that are only revealed in compound knockouts.
In Xenopus, p53 depletion results in embryonic lethality due to
gastrulation failure and defects in mesendoderm development
(Cordenonsi et al., 2003). A possible explanation for the differ-
ence between mice and frogs is that in early mouse embryos
the p53 family members p63 and p73 compensate for p53
loss, whereas in Xenopus p73 is absent and p63 is only ex-
pressed at later stages of development (Cordenonsi et al.,
2003).
Skeletal muscle differentiation (myogenesis) involves a cas-
cade of muscle-specific gene expression that is coordinated
with permanent withdrawal from the cell cycle. The commitment
of cells to the myogenic lineage and progression through the
myogenic differentiation process requires the bHLH transcrip-
tion factor family of myogenic regulatory factors (MRFs), includ-
ing MyoD, Myf5, Myogenin, and MRF4 (Puri and Sartorelli,
2000). Whereas early markers of the myogenic program, such
as Myogenin, can be expressed in proliferating cells, late
markers of the differentiation program, including muscle struc-
tural genes like myosin heavy chain (MHC), are induced only af-
ter cell cycle withdrawal. The retinoblastoma tumor suppressor
protein (RB) plays a critical role in establishing the G0 arrest ob-
served in differentiated myocytes, and muscle cells lacking RB
fail to exit the cell cycle (Novitch et al., 1996; Zacksenhaus
et al., 1996). In addition, RB is specifically required for execution
of the later steps in skeletal myogenesis, and its absencemolec-
ularly uncouples the early and late phases of this differentiation
program (Novitch et al., 1996). Although the last few years have
revealed some of the molecular mechanisms underlying the co-
operation of RB and differentiation-specific transcription factors
in the execution of specific transcription programs during termi-
nal differentiation, themechanisms that activate RB duringmyo-
genesis and other cellular differentiation processes still remain
unclear. Here, we report that the p53 family members have es-
sential functions in the activation of RB during physiological
myogenesis. These functions are commonly disabled in rhabdo-
myosarcoma (RMS) patients, indicating that differentiation con-
trol is a critical tumor suppressor activity of the p53 family.
Results
DNp73 interferes with myogenic differentiation
We have previously shown that DNp73, a p73 isoform that func-
tions as a transdominant inhibitor of all other p53 family mem-
bers, interferes with multiple developmental programs (Hu¨t-
tinger-Kirchhof et al., 2006). To understand the mechanistic
basis, we investigated the impact of DNp73 on myogenic differ-
entiation in more detail. For these studies, we used C2C12myo-
blasts that faithfully mimic skeletal muscle differentiation in vitro
(Blau et al., 1985). Upon shift to differentiation medium, mock
myoblasts stopped proliferating, elongated, aligned, and fused
to multinuclear myotubes. In contrast, myoblasts expressing
DNp73awithin the physiological range following retroviral trans-
duction continued to proliferate and failed to form differentiated
myotubes (Figure 1A; Figure S1A in the Supplemental Data
available with this article online). The absence of myotubes in
the DNp73a population was further confirmed by immunofluo-
rescence staining and immunoblotting for myosin heavy chain282(MHC) as a marker of mature muscle fibers (Figure S1B; Fig-
ure 1B). Similarly, primary human skeletal muscle myoblasts
transduced with a DNp73a-expressing lentivirus failed to form
myotubes and express muscle creatine kinase (Figures 1C
and 1D).
To test whether DNp73a can also override myogenic differen-
tiation signals induced by a 3D tissue environment, the differen-
tiation of C2C12 cells after incorporation into 3D fibrillar collagen
was investigated in the presence of serum.Whereas mockmyo-
blasts upregulated MHC and differentiated into multicellular
muscle fiber-like structures, DNp73a prevented MHC upregula-
tion and maintained a dispersed single-cell state (Figure 1E).
Thus, DNp73a overrides synergistic growth factor and ECM-
induced differentiation signals.
Defects of terminal cell cycle withdrawal in
DNp73a myoblasts
In growth factor-rich medium, mock and DNp73a myoblasts
showed no significant difference in their proliferation rate
(Figure 1F). Under conditions of mitogen deprivation, mock
myoblasts completely withdrew from the cell cycle within 1
day. In contrast, DNp73a myoblasts slowed down markedly
but continued to proliferate, resulting in a progressive increase
in cell number. Cell cycle profiles demonstrated that only few
mock cells (6%) remained in S phase 2 days after differentiation
induction compared to more than 22% of the DNp73a cells
(Figure 1G). Similarly, expression of the proliferating cell nuclear
antigen (PCNA) was completely repressed in mock but not in
DNp73a cells (Figure 1H). Importantly, cell cycle withdrawal dur-
ing myogenic differentiation is known to be permanent, and re-
stimulation with growth factors did not cause cell cycle reentry
(Figure 1I). All nuclei within multinuclear, MHC-expressing myo-
tubes failed to incorporate BrdU. In contrast, DNp73a cells rap-
idly increased their proliferation rate and showed a BrdU incor-
poration index of more than 90% (Figures 1I and 1J). These data
indicate that DNp73a myoblasts are sensitive to growth factor
depletion and slow down their proliferation rate but fail to per-
manently withdraw from cell cycle progression.
Genome-wide expression analysis of differentiation
in DNp73a myoblasts
The myogenic differentiation program is initiated by a limited set
of transcription factors that progressively unfold a complex pro-
gram of gene expression (Bergstrom et al., 2002; Delgado et al.,
2003).DNp73a is a protein with sequence-specific DNA-binding
properties, suggesting that it directly interferes with the expres-
sion of critical genes during differentiation (Grob et al., 2001;
Kartasheva et al., 2002; Stiewe et al., 2002a). We monitored
the differentiation process of mock and DNp73a myoblasts by
gene expression profiling with Affymetrix GeneChip Mouse
Genome 430 2.0 Arrays. We extracted total RNA from cells at
three different time points (0, 6, and 24 hr) after they had been
induced to differentiate. To distinguish differentiation-associ-
ated changes in gene expression from experimental noise, we
extracted all genes that were induced or repressed by more
than 3-fold at 6 or 24 hr compared to the 0 hr time point (Table
1). The expression levels of these 646 genes correlated between
the two cell types both in proliferation medium and 6 hr after in-
duction of differentiation. Only 23/646 genes (3.6%) were ex-
pressed differentially in the two cell types at the 0 hr and 19/
646 (2.9%) at the 6 hr time point. In contrast, 24 hr after inductionCANCER CELL OCTOBER 2006
A R T I C L EFigure 1. DNp73 interferes with cell cycle exit
and differentiation of myoblasts
A: Phase-contrast micrographs of proliferating
(GM) and differentiating (DM) mock and
DNp73a-expressing C2C12 myoblasts. Scale
bar, 100 mm.
B: Immunoblot for DNp73a, MHC, and actin.
C and D: Differentiation of mock and DNp73a-
transduced primary human skeletal muscle myo-
blasts (HSMM). C: Phase-contrast micrographs
on day 3 of differentiation. Scale bar, 200 mm.
D: Semiquantitative RT-PCR for muscle creatine
kinase (MCK) and GAPDH. The asterisk denotes
a band of primer dimers.
E: Mock and DNp73a-expressing myoblasts were
cultured in anchored 3D collagen lattices for 5
days, fixed, stained for F-actin (green) and
MHC (red), and three-dimensionally recon-
structed by confocal fluorescence microscopy.
Images show a depth of 400 mm.
F: Proliferation curve of mock (solid line) or
DNp73a (dashed line) myoblasts in proliferation
(GM) and differentiation medium (DM).
G and H: Cell cycle profiles (G) and immunoblot
for PCNA (H) of indicated myoblasts under prolif-
erating and differentiating conditions.
I: Proliferation curve of mock (solid line) and
DNp73a (dashed line) myoblasts during differen-
tiation (DM) and subsequent restimulation with
10% FCS (DM).
J: Immunofluorescence staining for MHC (red),
BrdU (green), and DAPI (blue) of differentiated
myocytes 24 hr after restimulation with FCS.
Scale bar, 50 mm.
Data are reported as the mean 6 standard
deviation.of differentiation 261/646 genes (40.4%) were expressed differ-
ently (>3-fold) between the two cell types (Figure 2A). Further-
more, in mock cells 73/646 genes showed a more than 3-fold
expression change during the first 6 hr. Of these 73 genes, 53
(72.6%) were also altered in the DNp73a myoblasts. Between
6 hr and 24 hr of differentiation, expression of 188/646 genes
changed more than 3-fold in the mock cells. However, expres-
sion of only 5 (2.6%) of these 188 genes changed in DNp73a
cells (Figure 2B). These data show that DNp73a-expressing
myoblasts respond to differentiation stimuli with immediate-CANCER CELL OCTOBER 2006early gene expression changes but fail to show the profound
changes observed at 24 hr associated with execution of the
differentiation program.
Functional annotation of the list of 646 genes revealed the
presence of several muscle-related genes, known p53 target
genes, and genes related to cell proliferation (Figure 2C). In
mock cells the muscle-related genes (e.g., Acta1, Tncc, Myh1)
were induced or repressed most prominently at 24 hr of dif-
ferentiation. Consistent with the observed differentiation defect,
only a few changes were observed in DNp73a myoblasts.283
A R T I C L EFurthermore, as expected from the function ofDNp73 as a dom-
inant-negative inhibitor of p53 family members, most of the p53
target genes (e.g., p21Cdkn1a,Gadd45a) that showed expression
changes in the mock cells were unchanged in the DNp73a cells.
Finally, consistent with the defects in permanent cell cycle with-
drawal, a number of cell proliferation-related genes (e.g., Rfc3,
Ccna2, Pole, Pold1, Mcm2) failed to be silenced in the
DNp73a myoblasts. The validity of the gene expression data
was further verified by measuring the expression levels of se-
lected genes by semiquantitative RT-PCR (Figure 2D).
DNp73 interferes with the activation of RB
To locate the differentiation block more precisely, we investi-
gated the expression of typical muscle differentiation markers
(Figure 3A). MyoD andMyf5, which play roles in specifying mus-
cle lineage, were expressed at equivalent levels in proliferating
and differentiating myoblasts irrespective of genotype. Myoge-
nin, one of the first markers to be expressed after the onset of
differentiation, was also similarly expressed in both mock and
DNp73amyoblasts. In contrast, downstream targets of Myoge-
nin (MEF2C, MHC, CKM) were absent in DNp73a-expressing
cells. The block to differentiation therefore occurs primarily after
the Myogenin expression step.
It has previously been shown that Myogenin activity is com-
promised in RB-deficient myoblasts (Novitch et al., 1996). In
fact, in a direct comparison bothRb2/2 andDNp73a-expressing
fibroblasts stopped the MyoD-induced differentiation program
at the Myogenin step (Figure 3B). The similar phenotype of RB
loss and DNp73a expression suggested that RB function might
be compromised by DNp73a. In differentiating wild-type myo-
blasts, we observed an increase in RB protein amount and in
electrophoretic mobility, indicating a shift from inactive, hyper-
phosphorylated to active, hypophosphorylated RB species
(Figure 3C). This activation of RB was significantly reduced in
DNp73a myoblasts, and high levels of inactive, hyperphos-
phorylated RB were maintained over the differentiation time
course. Whereas the reduced levels of RB protein can be ex-
plained by transactivation defects of the Rb1 gene (Figure 3E),
the phosphorylation state of RB is regulated by cyclin-depen-
dent kinases. Whereas differentiating mock myoblasts downre-
gulated CDK2- and CDK4-associated kinase activity, DNp73a
cells displayed higher CDK activity under both proliferating
Table 1. p73 modulates the tumorigenicity of myogenic cell lines
Cell line Tumor frequency
C2C12-mock 0/20 (0%)
C2C12-DNp73a 1/20 (5%)
C2C12-IGF2 3/29 (10%)
C2C12-IGF2 + DNp73a 15/29 (52%)
C2C12-Pax3:Fkhr 0/15 (0%)
C2C12-Pax3:Fkhr + DNp73a 13/15 (87%)
Rh30-ns (bulk) 9/10 (90%)
Rh30-p73shRNA (bulk) 3/10 (30%)
Rh30-ns (clone) 23/25 (92%)
Rh30-p73shRNA (clone 1) 3/15 (20%)
Rh30-p73shRNA (clone 2) 2/10 (20%)
Rh30-p73shRNA (clone 3) 1/10 (10%)
Cells (53 106) of the indicated genotype were subcutaneously injected into
nude mice that were monitored for tumor development for 3 months.
Shown is the number of mice with a tumor, the total number of mice injected
with each cell type, and the percentage of mice with tumors.284and differentiating conditions (Figure 3D). In mock myoblasts,
CDKs are typically inactivated by repression of cyclins and in-
duction of CDK inhibitors (Figure 3C). In contrast, DNp73a cells
maintained detectable levels of cyclins E and D and failed to in-
duce expression of the CDK inhibitors p21 and p57 (Figures 3A
Figure 2. DNp73a prevents differentiation but not immediate-early gene
expression changes in response to differentiation stimuli
A:Gene expression profiles of mock andDNp73aC2C12 myoblasts were an-
alyzed under proliferating conditions (GM, 0 hr) or 6 and 24 hr after induction
of differentiation. A list of 646 genes changed by more than 3-fold during the
time course of differentiation was extracted (Table S1). Scatter plots com-
paring the expression levels of these selected genes between mock and
DNp73a cells are shown.
B:Gene expression levels for a subset of genes that are altered within the first
6 hr of differentiation (n = 73, upper panel) or between the 6 and 24 hr time
points of differentiation (n = 188, lower panel).
C: Gene expression levels for subsets of genes that are muscle related (up-
per panel), p53 target genes (middle panel), or related to cell proliferation
(lower panel).
D: Semiquantitative RT-PCR analysis of differentiating C2C12 myoblasts.CANCER CELL OCTOBER 2006
A R T I C L EFigure 3. DNp73a interferes with RB activation in
myoblasts
A and B: Semiquantitative RT-PCR of genes criti-
cally involved in myogenic differentiation of
C2C12 myoblasts (A) and 3T3 fibroblasts (wild-
type, DNp73a-transfected, Rb2/2) after transfec-
tion with MyoD (B).
C: Immunoblot of mock and DNp73a myoblasts
harvested at the indicated time points of differ-
entiation.
D: CDK activity in proliferating (GM) and day 3
differentiated (DM) myoblasts. Kinase activity of
CDK2 and CDK4 immunoprecipitates was deter-
mined with histone H1 and GST-RB as substrates.
E: qRT-PCR of RB expression in differentiating
C2C12-mock (black bars) and C2C12-DNp73a
cells (gray bars). Expression levels were normal-
ized to GAPDH and expressed as the fold
change compared to proliferating C2C12-
mock cells.
F: Rescue experiment. C2C12-DNp73amyoblasts
infected with the indicated adenoviruses were
shifted to differentiation medium for 2 days. The
morphology of the infected cells is shown by
GFP fluorescence microscopy. Scale bar, 100mm.
G and H: Immunoblot of C2C12-DNp73a cells
differentiated after infection with indicated ade-
noviruses.
Data are reported as the mean 6 standard
deviation.and 3C). These findings explain the inability to activate RB and
the failure of DNp73amyoblasts to exit the cell cycle and induce
muscle-specific gene expression.
To investigate if the observed defect in RB activation is caus-
ally related to the block in differentiation, we tried to rescue the
differentiation defect with ectopic expression of RB (Figures 3FCANCER CELL OCTOBER 2006and 3G). For this, DNp73a myoblasts were infected with re-
combinant adenoviruses expressing wild-type RB (AdGFP-
RBwt), a constitutively active phosphorylation site mutant of
RB (AdGFP-RBmut), or an empty virus control (AdGFP). Only
cells expressing the constitutively active form of RB stopped
proliferating and exhibitedmorphological and biochemical signs285
A R T I C L EFigure 4. Role of p53 family members in myo-
genic differentiation
A–D: Expression of p53 family members and dif-
ferentiation markers during in vitro differentiation
of primary mouse myoblasts. A and B: Semiquan-
titative RT-PCR. C: Immunoblots. D: Quantifica-
tion ofDNp63aand TAp73bprotein levels by den-
sitometric analysis.
E: C2C12 myoblasts were transiently transfected
with the indicated expression plasmids and ana-
lyzed by semiquantitative RT-PCR.
F: C2C12 myoblasts were harvested under prolif-
erating conditions and 36 hr after induction of
differentiation. Association of p53, p63, and
TAp73 with the Rb1, p57KIP2, and p21Cdkn1a pro-
moters was analyzed by chromatin immunopre-
cipitation. For p57KIP2 the fragment 2966/2757
upstream of the first exon (Ensembl transcript
ENSMUST00000037287) was amplified.of differentiation (Figure 3F, lower panel; Figure 3G). Immuno-
blots showed that wild-type RB was inactivated by hyperphos-
phorylation and therefore unable to induce differentiation.
However, in combination with p57 (AdGFP-p57), hyperphos-
phorylation of wild-type RB was prevented, resulting in expres-
sion of MHC (Figure 3H). Lower MHC levels induced by the ad-
enoviral combination compared to the constitutively active RB
mutant most likely reflect the low rate of coinfection with two dif-
ferent adenoviruses. p57 alone prevented RB phosphorylation
but also decreased RB protein levels to barely detectable levels.
Therefore, both p57 induction and an increase in RB expression
are required to obtain levels of active RB that support comple-
tion of the differentiation program. In summary, active RB in
the form of a constitutively active mutant or as a combination
of wild-type RB with p57 rescued the DNp73a-induced differen-
tiation block, proving that defects in activating RB are indeed the
underlying cause.
Individual p53 family members in myogenic
differentiation
Since DNp73a functions as a dominant-negative inhibitor of the
transactivation-competent p53 family members, DNp73amight
inhibit the activation of RB by interfering with essential functions286of the individual p53 family members. In primary murine myo-
blasts (Figures 4A–4D) and C2C12 myoblasts (Figure S2A and
S2B), all p53 family members were expressed. Although p53
mRNA levels increased progressively over 3 days, this was not
accompanied by an increase in p53 protein levels. Considering
the previously reported increase in p53 activity during myogenic
differentiation (Porrello et al., 2000), our results suggest that the
differentiation function of p53might not be regulated on the level
of protein stability.
On the mRNA level, expression of both DNp63 and TAp73
peaked around day 1. TAp63 and DNp73 mRNAs were detect-
able but unchanged over the time course of differentiation.
The analysis of p73 (and p63) proteins is complicated by the
multitude of different isoforms and the lack of isoform-specific
antibodies that are suitable for detection of endogenous p73
in the mouse (Sayan et al., 2005). Here, we used a polyclonal
p73 antibody raised against a common epitope and identified in-
dividual isoforms by comparison to myoblasts transfected with
specific isoforms (Figure S2B). The most prominent changes
are an increase in DNp63a and TAp73b expression at 12 to 36
hr (Figures 4C and 4D). In fact, TAp73bwas the only p73 isoform
detected by themonoclonal p73 antibodyGC15 in primarymyo-
blasts differentiated for 24 hr (Figure S2B). Importantly, theCANCER CELL OCTOBER 2006
A R T I C L EFigure 5. Specific functions for individual p53 family members in myogenic
differentiation
A: C2C12 myoblasts were transduced with p53DD, p73DD, or both (2xDD).
Following selection, expression of the constructs was verified by immuno-
blotting. The differentiation potential of these cells was analyzed 3 days af-
ter shift to differentiation medium by immunofluorescence staining for MHC
(red) (B), calculation of the differentiation index (C), and immunoblotting for
MHC (D). Scale bar, 100 mm. E: Expression of genes involved in muscle differ-
entiation analyzed by RT-PCR. F: C2C12 myoblasts were transfected with
shRNA constructs directed against p53, p63, and p73. A nonsilencing shRNA
was used as a control. The knockdown efficiency was analyzed by RT-PCR.CANCER CELL OCTOBER 2006increase in p63/p73 expression coincides with induction of p21
and p57 and decreased phosphorylation of RB. Similar expres-
sion changes were observed in regenerating muscles in vivo
(Figure S3).
When ectopically expressed, all themajor transactivating pro-
teins of the p53 family (p53, TAp73b, TAp63g) induced the Rb1
and p21Cdkn1a genes (Figure 4E), which have typical p53-binding
sites in their promoter regions (Porrello et al., 2000). In contrast,
consistent with recent reports, p57KIP2 was transactivated only
by TAp73b and DNp63a but not by p53 (Beretta et al., 2005;
Balint et al., 2002; Vaccarello et al., 2005). The analysis of the
sequences upstream of the p57KIP2 transcriptional start or in
the introns of p57KIP2 failed to reveal any p53-binding sites
arranged in tandem, as usually is seen in p53-responsive pro-
moters. Considering the lack of p53 responsiveness, the ab-
sence of typical p53-binding sites is not surprising and suggests
that other mechanisms of promoter targeting are employed by
TAp73b and DNp63a. The experiment further revealed that,
although both TAp73a and DNp73a failed to transactivate
Rb1, p21Cdkn1a, and p57KIP2, only DNp73a had dominant-nega-
tive activity when coexpressedwith p53 or TAp73b (Figure S2C).
We next analyzed if Rb1, p21Cdkn1a, and p57KIP2 are indeed
regulated by the p53 family in differentiating myoblasts and in-
vestigated recruitment of p53, p63, and TAp73 to the respective
promoter regions by chromatin immunoprecipitation (Figure 4F).
Whereas none of the investigated proteins was associated with
the Rb1 and p57KIP2 promoters in proliferating myoblasts, upon
differentiation p53 bound to the Rb1 promoter, and p63 and
TAp73 were recruited to the p57KIP2 promoter. The p21Cdkn1a
promoter was bound most strongly by p53 and only weakly by
p63/p73. Binding was already detected in proliferating myo-
blasts and increased slightly during differentiation.
Dominant-negative inhibitors or knockdown of p53
family members compromises myogenic differentiation
To test the requirement for individual p53 family members in
myogenic differentiation, we used previously validated domi-
nant-negative inhibitors, which allow us to specifically ablate
the function of either p53 (p53DD) or p63/p73 (p73DD) (Irwin
et al., 2000, 2003). Single inhibitors reduced the differentiation
index from 24% in the mock myoblasts to 8% (p53DD) or 9%
(p73DD), respectively (Figures 5A–5D). The combination of
both inhibitors further reduced the differentiation index to less
than 2%, supporting the hypothesis that p53 and p63/p73
have different but complementary functions in differentiation
control. The effect of DNp73a could therefore be mimicked by
the combination of two dominant-negative inhibitors, indicating
that the dominant-negative function of DNp73awas sufficient to
block myogenic differentiation. Similar to DNp73a, the two in-
hibitors (alone or in combination) had no significant effect on
Myogenin expression but reduced expression of MHC and
MCK cooperatively to barely detectable levels (Figure 5E). Fur-
thermore, the analysis revealed that RB induction was primarily
G: MHC, RB, and p57 expression was analyzed in these cell populations at
the indicated time points of differentiation by RT-PCR. H: C2C12 myoblasts
were transfected with shRNA constructs directed against p21 and p57 as in-
dicated. The knockdown efficiency and MHC expression were analyzed by
semiquantitative RT-PCR before and 3 days after induction of differentia-
tion. I: Differentiation index of p21 and p57 knockdown cells on day 5 of dif-
ferentiation. Data are reported as the mean 6 standard deviation.287
A R T I C L Einhibited by p53DD, whereas p57 induction was impaired by
p73DD. This confirmed that the p53 family members coordinate
progression to later stages of differentiation by regulating RB.
To rule out effects of p53DD and p73DD unrelated to their
dominant-negative function, we also used RNA interference as
an independent method. Specific knockdown of single p53 fam-
ily members resulted in impaired differentiation using MHC ex-
pression as a read-out (Figures 5F and 5G). Inhibition of p53
compromised RB induction (see Figure S4A for qRTPCR),
whereas shRNAs directed against either p63 or p73 interfered
with p57 induction. Both p63 and p73 were essential for regula-
tion of p57, as the knockdown of either factor blocked p57 ex-
pression. In support of these data, p532/2 myoblasts failed to
induce RB, whereas p732/2myoblasts showed impaired induc-
tion of p57 (Figures S4B–S4D). As p63-deficient mice die at birth
with severe limb truncations, comparable differentiation studies
could not be performed on p632/2 myoblasts.
As these data suggested regulation of CKIs as the critical
activity of p63/p73 in differentiation, we investigated the effects
of p21 and p57 depletion (Figures 5H and 5I). Whereas the
knockdown of either CKI had no significant impact, the com-
bined depletion significantly reduced differentiation and mimics
a loss of p53 family functions. The data correlate with the
chromatin immunoprecipitation results and support the hypo-
thesis of a functional dichotomy in the p53 family with respect
to differentiation control. p53 on the one side regulates RB
expression, and p63 and p73 on the other side are in control of
p57. The two p53 family functions are complementary and
cooperate to activate RB, which is essential for efficient myo-
genic differentiation.
Malignant transformation of myoblasts by DNp73a
Differentiation failure is a characteristic feature of rhabdomyo-
sarcoma (RMS), the most common soft tissue sarcoma in chil-
dren.We therefore investigatedwhetherDNp73a has oncogenic
functions in RMS. However, C2C12-DNp73amyoblasts failed to
form tumors in nude mice, indicating that inhibition of differenti-
ation is not sufficient for tumor formation (Table 1). Since single
oncogenes are rarely sufficient to induce transformation, we
tested cooperation of DNp73a with the known RMS oncogenes
IGF2 and Pax3:Fkhr (Merlino and Helman, 1999). DNp73a in-
hibited the differentiation of parental and Pax3:Fkhr myoblasts
and also the accelerated and enhanced differentiation of IGF2
myoblasts (Figure 6A) (Stewart et al., 1996). Of these various
myoblast populations, only IGF2+DNp73a and Pax3:Fkhr+
DNp73a cells were tumorigenic in nude mice (Table 1). To un-
derstand why single oncogenes do not result in tumor formation
whereas combinations together with DNp73a do, we injected
the cells mixed with Matrigel Matrix into the subcutis of mice
and explanted the Matrigel plugs after 1 week (Figure 6B). Ma-
trigel plugs of Pax3:Fkhr myoblasts contained few cells in the
center but were surrounded by a dense rim of MHC-positive
cells that frequently fused into multinuclear myotubes. In con-
trast, matrigel plugs containing Pax3:Fkhr+DNp73a myoblasts
showed no MHC staining and contained areas of active prolifer-
ation as shown by PCNA staining. These findings demonstrate
that myoblasts injected into mice exit the cell cycle and differen-
tiate into mature myotubes irrespective of Pax3:Fkhr expres-
sion. DNp73a interferes with cell cycle withdrawal and differen-
tiation and thus unleashes the oncogenic activities of Pax3:Fkhr
(and IGF2) and enables tumor growth.288Oncogenic function of DNp73 in human
rhabdomyosarcoma
Inspired by the role of DNp73a as a cooperating oncogene in
myoblasts, we investigated p73 expression in tumor samples
from rhabdomyosarcoma patients. As long as no isoform-
specific antibodies are available for the immunohistochemical
detection of endogenous DNp73 proteins, RT-PCR remains
themethod of choice for quantification of p73 isoforms in limited
amounts of tumor tissues (Sayan et al., 2005; Stiewe et al.,
2002b, 2004; Zaika et al., 2002). Whereas no p73 expression
was detectable in normal muscle tissues and undifferentiated
human skeletal muscle myoblasts (HSMM), various p73 iso-
forms were expressed to high levels in the majority of patient
samples (Figure 6C). High TAp73 levels were seen in 85.7% of
patients and were always associated with overexpression of
DNp73 generated by either alternative splicing of exon 2
(DNAS) or alternative promoter usage (DNAP). Further immuno-
histochemical analyses indicated that RB and p57 are inversely
regulated. Whereas normal muscle tissue showed a strong p57
staining associated with undetectable RB staining, two rhabdo-
myosarcoma tissues showed barely detectable p57 staining
combinedwith high levels of RB (Figure 6D). Importantly, a rhab-
domyosarcoma with high DNp73a expression (sample #20) dis-
played a significantly higher phospho-RB staining index than
a low DNp73-expressing tumor (sample #22), providing further
support thatDNp73 regulates RB activity by controlling its phos-
phorylation state (Figure 6D).
Similar to the primary tumor samples, three of five RMS cell
lines (including the Rh30 cell line) showed concomitant overex-
pressionof TAp73andDNp73onboth theRNAandprotein levels
(Figures 7A and 7B). As DNp73a, which counteracts the antipro-
liferative activity of TAp73 (Figure S5A), is known to efficiently se-
quester TAp73 (and also p63) in transcriptionally inactive com-
plexes, DNp73a is likely the dominant isoform (Grob et al.,
2001; Slade et al., 2004; Stiewe et al., 2002a). To investigate if
high p73 expression contributes to the differentiation defect
and the tumorigenic phenotype, we depleted p73 in Rh30 cells
using RNA interference (Figure 7C). Whereas cells transduced
with a nonsilencing control shRNA induced tumors in 32 of 35
nude mice (91.4%), cells with silenced p73 expression formed
tumors in only 9 of 45mice (20.0%) (Table 1). Analysis of individ-
ual clones further demonstrated that the decrease in tumorige-
nicity directly correlated with the degree of p73 depletion. We
further analyzedwhether inhibition of p73 also affects the growth
of established RMS tumors that developed 4weeks after subcu-
taneous injection of parental Rh30 cells into nude mice. For
in vivo gene delivery, we generated a recombinant adenovirus
(AdGFP-p73shRNA) that efficiently reduced p73 expression in
Rh30 cells by RNA interference (Figure 7E). Following an intratu-
moral injection of 53 107 PFU of AdGFP-p73shRNA but not the
control adenovirus (AdGFP-ns) we observed a significant retar-
dation of tumor growth (p < 0.002) over a period of 5 weeks (Fig-
ure 7D). To understand the mechanisms underlying this growth
inhibition, we further investigated the effects of p73 knockdown
in Rh30 cells in vitro. Depletion of p73 induced p57, providing
evidence that DNp73a is indeed a negative regulator of p57 ex-
pression in RMScells, as suggested by the initial overexpression
studies in C2C12 myoblasts (Figure 7E).
However, p73 depletion did not result in differentiation but
induced a cell cycle arrest instead (Figure 7F; Figure S5B). This
effect on cell proliferation is also supported by a clonogenicCANCER CELL OCTOBER 2006
A R T I C L EFigure 6. DNp73a in rhabdomyosarcoma devel-
opment
A and B: DNp73a cooperates with IGF2 and
Pax3:Fkhr in the malignant transformation of
myoblasts. A: C2C12 myoblasts were trans-
duced with retroviral constructs for IGF2,
Pax3:Fkhr, and DNp73a. Empty vectors were
used as controls. Following selection, the differ-
entiation potential was analyzed by immunoflu-
orescence staining for MHC. The calculated dif-
ferentiation index is shown. B: Pax3:Fkhr (Bi and
Bii) and Pax3:Fkhr+DNp73a (Biii and Biv) myo-
blasts were mixed with Matrigel Matrix HC and
injected s.c. into nude mice. After 1 week, the
Matrigel plugs were excised and analyzed by
immunohistochemistry for MHC (Bi and Biii) or
PCNA (Bii and Biv). Scale bar, 100 mm.
C: Expression of full-length (TAp73) and N-termi-
nally truncated p73 isoforms generated by alter-
native splicing of exon 2 (DNAS) or alternative
promoter usage (DNAP) was investigated in nor-
mal muscle and RMS tissues by semiquantitative
RT-PCR. Human skeletal muscle myoblasts
(HSMM) were used as a control.
D: Immunohistochemistry of two rhabdomyosar-
coma samples, lanes 20 and 22 in C, and a nor-
mal muscle tissue for total RB, serine 807/811
phosphorylated RB, and p57. Scale bar, 50 mm.
Data are reported as the mean 6 standard
deviation.formation assay demonstrating reduction in colony size but not
colony number following p73 knockdown (Figure 7G). To under-
standwhy restoration of p57 expression by depletion ofDNp73a
is not sufficient to induce differentiation, we tried to rescue the
differentiation defect directly by overexpression of p57. How-
ever, this approach also failed to rescue the differentiation de-
fect, althoughp57 inducedefficient dephosphorylation of the en-
dogenous RB protein (Figure 7H). Simultaneously, however, RB
expression was reduced to barely detectable levels, reminiscent
of our observations inC2C12-DNp73acells (Figure 3H). Restora-
tion of RB levels by coexpression of RB together with p57 re-
sulted in high levels of ‘‘active RB’’ that proved sufficient forCANCER CELL OCTOBER 2006differentiation (Figure 7H). Similarly, wild-type RB was efficiently
activated in p73-depleted Rh30 cells again, resulting in morpho-
logical and biochemical signs of differentiation (Figure 7I). This
indicates that differentiation of rhabdomyosarcoma cells re-
quires the same two pathways shown to be important for the dif-
ferentiation of nontransformed myoblasts: the p63/p73-p57 and
the p53-RB pathways (Figure 7J). In Rh30 cells, induction of p57
by p63/p73 is blocked by DNp73a, whereas transactivation of
the RB gene is prevented by a mutation in p53. Correction of
these two common RMS-associated alterations by direct over-
expression of RB and p57 as the twomain downstreameffectors
of p53 and p63/p73, respectively, rescues the differentiation289
A R T I C L EFigure 7. p73 functions as an oncogene in RMS
A and B: Human RMS cell lines (1, JR-1; 2, RD; 3,
Rh30; 4, Rh18; 5, Rh41) and primary human fibro-
blasts (6, BJ) as a control were analyzed for p73
expression by isoform-specific RT-PCR (A) and
immunoblotting (B).
C: Rh30 cells were infected with lentiviruses ex-
pressing a p73-directed shRNA or a nonsilencing
shRNA as a control. Bulk cultures and individual
clones were expanded, and endogenous p73
expression was analyzed by immunoblotting.
D: Rh30 cells (5 3 106) were injected subcutane-
ously into nude mice. After 4 weeks, 5 3 107 PFU
of recombinant adenoviruses generating nonsi-
lencing (AdGFP-ns) or p73-directed shRNAs
(AdGFP-p73shRNA) were injected into estab-
lished tumors of approximately 100 mm3 volume
(n = 5 for each treatment). Shown are the tumor
volumes and the standard deviation (two-way
ANOVA, p < 0.002).
E and F: Rh30 cells were infected for 2 days with
a low (50 moi) or high (200 moi) dose of AdGFP-
ns or AdGFP-p73shRNA. E: Immunoblot for p73,
p57, and b-actin. F: Immunofluorescence stain-
ing for the proliferation marker Ki67. Scale bar,
100 mm.
G: Clonogenic formation assay. Rh30 cells were
transfected with plasmids encoding nonsilenc-
ing or p73-directed shRNAs and selected with
puromycin for 2 weeks. Shown is a quantitative
analysis of the total colony area, the average
colony number per dish, and the average col-
ony size. A representative Giemsa staining is
shown on the right.
H: Rescue experiment. Rh30 cells were infected
with the indicated adenoviruses and shifted to
differentiation medium for 3 days. Expression of
MHC, RB, serine 807/811 phosphorylated RB,
p57, and b-actin is shown by immunoblotting.
I: Rh30 cells were infected with a combination of
AdGFP-RBwt and AdGFP-ns or AdGFP-
p73shRNA, respectively. After 3 days in differenti-
ation medium, differentiation was analyzed by
fluorescence microscopy and immunoblotting
for MHC, RB, and phospho-RB (S807/811). Scale
bar, 100 mm.
J: Role of p53 family members during myogenic
differentiation. Alterations found in rhabdomyo-
sarcoma samples and their impact on the differ-
entiation program are shaded in gray.
Data are reported as the mean 6 standard
deviation.defect and therefore identifies dysfunction of p53 family-regu-
lated differentiation pathways as the underlying cause of the fail-
ure of rhabdomyosarcoma cells to differentiate.
Discussion
In our study we show that all p53 family members cooperate to
activate the differentiation function of RB, which is required for
both the permanent cell cycle exit and the activation of290muscle-specific genes. Whereas p53 regulates RB protein
levels, p63 and p73 control the activity of RB by regulating its
phosphorylation state via the CKI p57KIP2 (Figure 7J). RMS cells
maintain RB in the hyperphosphorylated state when exposed to
mitogen-poor differentiation-inducing media, explaining in
part their failure to arrest growth or differentiate under these
conditions (Knudsen et al., 1998). Similarly, myoblasts trans-
fected with DNp73a maintain hyperphosphorylated RB and
fail to differentiate. Transfection with active forms of RBCANCER CELL OCTOBER 2006
A R T I C L E(phosphorylation-insensitive RB or the combination of wild-
type RB with p57) rescues the differentiation defect of both
DNp73a-transfected myoblasts and RMS cells that express
high endogenous levels of DNp73. This provides compelling
evidence that RB dysfunction in RMS can be caused by genetic
alterations that affect the function of the p53 family in differenti-
ation control.
In addition to p57, p21 is another CKI involved in RB regula-
tion, and only mice deficient for both p57 and p21 have severe
muscle defects (Zhang et al., 1999). The p21CIP1 promoter con-
tains characteristic p53-binding elements and is activated by
ectopic expression of all transactivating p53 family members
(Figure 4D). However, during muscle differentiation p21 induc-
tion has been previously shown to be p53 independent, which
has been explained by direct induction of p21 by MyoD (Parker
et al., 1995). In our experiments DNp73a reduced but did not
completely abrogate p21 induction (Figure 3C). The severe dif-
ferentiation defect of DNp73a myoblasts, however, demon-
strates that the low levels of p21 seen in the absence of p53
family function are inadequate to support differentiation. Fur-
thermore, depletion of neither p57 nor p21 was alone sufficient
to inhibit differentiation. Only the combined knockdown of both
p57 and p21 significantly compromised the differentiation pro-
cess (Figures 5H and 5I). Therefore, although p53 itself might
be dispensable (Parker et al., 1995), the p53 family as a whole
is certainly required for p21 to reach levels needed for complet-
ing the differentiation program.
Considering the profound impact of DNp73 on myogenic dif-
ferentiation, it appears remarkable that none of the homozygous
knockout mice of single p53 family members have an overt mus-
cle phenotype. p53 null mice show normal muscle development,
although p53-deficient myoblasts fail to induce RB, resulting in
deficient MHC expression upon differentiation in vitro (Porrello
et al., 2000; Figure 5G; Figure S4B). In our experiments the
Rb1 gene was transactivated not only by p53 but also by
TAp63g and TAp73b (Figure 4D), suggesting that p63/p73might
be able to compensate for p53 loss in the microenvironment of
the myotome or the regenerating muscle tissue in vivo.
Although both p63 and p73 knockout mice present with de-
velopmental defects, severe muscle abnormalities have not
been reported (Moll and Slade, 2004). However, in our experi-
ments RNAi-mediated knockdown of either factor was sufficient
to inhibit p57 induction and impaired the progression to late
stages of differentiation. Furthermore, myoblasts from p73
knockout mice showed a significant reduction in p57 expression
(Figures S4C and S4D). However, as p73 and p63 are both in-
volved in regulation of p57 expression, developmental plasticity
in signaling pathways might allow p63 to compensate for p73
loss and vice versa in vivo. Considering the similar function of
the two proteins in the differentiation process, functional com-
pensation appears very likely, so that amuscle phenotype in vivo
might only become apparent in homozygous compound double
or triple knockouts.
A role for p53 in suppression of RMS development has been
previously suggested. p53+/2 mice over a year old develop
mostly sarcomas, 19%of which are RMS (Choi and Donehower,
1999). Furthermore, conditional Pax3:Fkhr knockin mice de-
velop RMS frequently on a p53-compromised background but
only very rarely in p53-proficient mice (Keller et al., 2004). Apart
frommouse studies, the Li-Fraumeni cancer syndrome, which is
associated with germline p53 mutations, was initially identifiedCANCER CELL OCTOBER 2006from a RMS patient as the index case and includes these tumors
along with other soft-tissue sarcomas (Li and Fraumeni, 1969).
Interestingly, in many tumors p53 is inactivated by missense
mutations that endow p53 with new functions (‘‘gain-of-func-
tion’’), like the dominant-negative inhibition of the closely related
family members p63 and p73 (Di Como et al., 1999; Marin et al.,
2000). Therefore, many p53 mutations disable not only the
tumor-suppressive function of p53 but rather the function of
the complete family.
In addition, our study demonstrates that p73 is overexpressed
in themajority of RMS samples. Just as high p53 protein levels in
tumor tissues are an indicator for p53 mutations, high p73 levels
correlate with compromised p73 activity. In many tumors, p16-
RB-E2F pathway alterations result in elevated levels of the E2F-
target gene TAp73 (Irwin et al., 2000; Stiewe and Pu¨tzer, 2000;
Zaika et al., 2001). Increased TAp73 expression in tumors in
turn is frequently associated with the generation of aberrantly
spliced DNp73 encoding transcripts (Stiewe et al., 2002b,
2004; Pu¨tzer et al., 2003) and in transactivation of the DNp73
promoter (Grob et al., 2001; Kartasheva et al., 2002). Consis-
tently, we observed simultaneous overexpression of both
TAp73 and DNp73 in RMS samples and found that DNp73 ex-
pression in Rh30 cells is driven by TAp73 (Figures S5C–S5F).
DNp73 forms transactivation-defective complexes with p73
(and also p63), resulting in the stabilization of p73 proteins on
a high, but transcriptionally inactive level (Slade et al., 2004).
In addition, DNp73 competes with p53 for binding to p53 target
promoters (Grob et al., 2001; Stiewe et al., 2002a). However,
higher concentrations of DNp73 are needed for inhibition of
p53 than for inhibition of p63/p73 (data not shown). Likewise,
most p53 missense mutations compromise p53 function, but
only a few have a dominant-negative effect on p63/p73 (Marin
et al., 2000). For example, although the p53 mutations 143A,
179Q, and 273H all abrogate p53 function, only the 143A and
179Q mutants inhibit transactivation by p73. DNp73 overex-
pression and p53 mutations can therefore cooperate to provide
complete inhibition of the p53 family and are not necessarily mu-
tually exclusive. An example is provided by the Rh30 cell line in
our studies, which contains a DNA contact mutation in p53
(R273C). Although not formally proven for the R273C mutant,
the similar R273H mutation prevents p53 from binding to target
promoters but has no dominant-negative effect toward p63 and
p73 (Marin et al., 2000). Although p63 and p73 are not inacti-
vated by the p53 mutant, they are sequestered by high levels
of DNp73. The importance of DNp73 overexpression for the tu-
morigenic phenotype even in the presence of a p53 mutation is
illustrated by the dramatic reduction of tumor growth following
RNAi-mediated knockdown of p73 in vivo. Consistent with
DNp73 being a repressor of p57 expression (Figures 3A and
3C), depletion of p73 in Rh30 cells resulted in a strong increase
in p57 levels associated with a cell cycle arrest (Figures 7E–7G).
Ectopic expression of p57 alone induced a similar cell cycle
arrest that was not associated with differentiation, presumably
because of a simultaneous reduction in RB protein levels (Fig-
ure 7H; data not shown). However, differentiation was observed
when RB was expressed together with p57 (Figure 7H) or ex-
pressed in the context of DNp73 depletion (Figure 7I), suggest-
ing that the p53-RB pathway is required to maintain high levels
of RB when p57 is induced by p63/p73. RB and p57 are there-
fore themajor downstream targets of the p53 family in myogenic
differentiation, and induction of both targets is typically impaired291
A R T I C L Eduring the development of RMS tumors by alteration of p53
family functions.
In summary, our experiments show that all p53 family mem-
bers are involved in regulating the process of muscle differenti-
ation.Whereas the early stepsof differentiation, up to expression
ofMyogenin, can occur in the absence of the p53 family, the later
stages involving permanent cell cycle exit and activation of
muscle-specific gene transcription require active RB, which is
dependent on p53 family functions. The functions of the individ-
ual members are distinct but complementary. p53 is required to
induce transcription of the RB gene, whereas p63 and p73 con-
trol expression of p57, which maintains RB in an active hypo-
phosphorylated state. Ablation of these p53 family functions
by overexpression of DNp73 or mutations in p53 blocks myo-
genic differentiation and enables cooperating oncogenes to
transform myoblasts to tumorigenicity. Induction of cellular dif-
ferentiation therefore contributes to the tumor suppressor activ-
ities of the p53 family and provides an explanation for the high
frequency of p53 pathway alterations in rhabdomyosarcoma.
Experimental procedures
In vivo experiments
For analysis of tumorigenicity, 5 3 106 cells were injected subcutaneously
into the flank of 4- to 6-week-old nude mice. Tumor volumes were measured
twice weekly using calipers. For later recovery, the cells were mixed withMa-
trigel Matrix HC (Becton Dickinson) before subcutaneous injection. After 1
week, the Matrigel plug was excised and processed for immunohistochem-
istry using standard procedures. For immunodetection of MHC and PCNA,
the M.O.M. Peroxidase Kit (Vector Laboratories) was used. For in vivo
gene delivery experiments, 53 106 Rh30 cells were subcutaneously injected
into nude mice. After 4 weeks, tumors with approximately 100 mm3 volume
were injected with 5 3 107 PFU of CsCl-purified adenoviral vector. Tumor
growth was measured twice weekly for a total of 6 weeks. All animal exper-
iments were performed according to protocols approved by the Bezirksre-
gierung Unterfranken.
Human rhabdomyosarcoma tissues
For analysis of human rhabdomyosarcoma tissues, 21 ex vivo RMS fresh-
frozen specimen containing 12 embryonal and 9 t(2;13) Pax3:Fkhr-positive
alveolar RMS were investigated by RT-PCR. This study was approved by
the Ethics Committee of the University of Wu¨rzburg, Germany, and informed
consent was obtained from all subjects.
Microarray experiments
Mock and DNp73a-expressing C2C12 myoblasts were analyzed under pro-
liferating conditions as well as 6 and 24 hr after the shift to differentiation me-
dium. Total RNA was extracted with TriPure Isolation Reagent (Roche). The
samples were analyzed for gene expression using Affymetrix GeneChip
Mouse Genome 430 2.0 Arrays and further analyzed with GeneSpring 7.0
(Silicon Genetics). Only genes flagged present or marginal in all samples
were included in the analysis. A list of 646 genes that were changed >3-
fold in mock myoblasts at 6 or 24 hr compared to the 0 hr time point was ex-
tracted (Table S1). The complete set of microarray data has been deposited
in NCBI’s Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/
geo/) and is accessible through GEO Series accession number GSE5447.
Statistical analysis
Statistical analysis of tumor growth curves was performed with GraphPad
Prism software using two-way ANOVA analysis. All numerical data are re-
ported as the mean 6 standard deviation.
Other procedures are described in the Supplemental Data.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and one supplemental table and can be found with this
article online at http://www.cancercell.org/cgi/content/full/10/4/281/DC1/.292Acknowledgments
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